The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000635369
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
24/03/2026
Date registered
Help: Date registered
26/05/2026
Date last updated
Help: Date last updated
26/05/2026
Date data sharing statement initially provided
Help: Data sharing statement date
26/05/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
The acute cycling exercise-induced inflammatory response on those with gastrointestinal disorders and healthy controls.
Scientific title
Effects of acute cycling, continuous vs interval, on L-1 receptor antagonist, monocyte chemoattractant protein-1 and interleukin-17 in gastrointestinal disorders and healthy controls - a randomised crossover trial.
Additional trial identifiers [1] 308380 0
Nil
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Inflammatory bowel disease 341220 0
Irritable bowel syndrome 341221 0
Condition category
Condition code
Oral and Gastrointestinal 337312 337312 0 0
Inflammatory bowel disease
Oral and Gastrointestinal 337313 337313 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Inflammatory and Immune System 337695 337695 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This study investigates the acute exercise-induced inflammatory response for a gastrointestinal group (GI), specifically inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), compared to healthy controls (HC), and further compared moderate-intensity continuous exercise (MICE) with high/low-intensity interval exercise (HIIE) as a randomised crossover protocol.

Prior to enrolment into the study, all participants were required to complete the Adult Pre-Exercise Screening System (APSS), a health history questionnaire, and the Depression, Anxiety, and Stress Scales-21 (DASS-21). Participants in the GI group completed an additional disease-specific questionnaire, either Harvey-Bradshaw Index (HBI), the Simple Clinical Colitis Activity Index (SCCAI) or the IBS-Symptom Severity Scale (IBS-SSS) for CD, UC, and IBS, respectively. Following pre-screening, and if satisfying the inclusion criteria, informed consent was obtained, and participants were enrolled into the study. Participants then completed an initial familiarisation and baseline testing session, which included measures of anthropometry, dual-energy x-ray absorptiometry (DEXA) scan, a graded exercise test (GXT), and a fasted blood sample.

After a 7 day (d) rest, participants completed two exercise protocols in a randomised, counter-balanced order separated by 7 d. For each testing session a fasted pre-exercise venous blood sample was taken and then immediately (0min), 2h and 24h post exercise. The exercise protocol, described subsequently, was 35 min in duration. The participants remained fasted throughout the exercise protocol and for the 2hr post exercise blood sample. Water was permitted throughout the fast, including throughout the exercise protocol and post-exercise, no food was permitted 8 hours prior to the exercise intervention.

Each participant was randomly allocated an acute exercise protocol that consisted of a 35min continuous stationary cycle ergometry (Monark 828E, Monark Exercise AB, Varburg, Sweden). The two exercise protocols were either moderate-intensity continuous exercise (MICE) or alternating high- and low- intensity interval exercise (HIIE). MICE was performed at 65% of VO2peak and HIIE was performed at a ratio of 2:3 (120s at 50% VO2peak: 180s at 80% VO2peak). The workload was calculated as a percentage of power output achieved in the GXT, then converted into kilopond units and set as a fixed workload of the MICE and alternating workload for the HIIE. Further, telemetry-based HR and RPE (Borg CR10 scale) were recorded every 5min throughout the protocol. Intravenous blood sampling was drawn at pre-exercise, immediately- (0min), 2h- and 24h- post cycling intervention. Gastrointestinal symptoms were individually monitored and reported during, post- and 24h after exercise. Following another 7 d rest period, the participants arrived at the laboratory to complete the second exercise protocol.

Each intervention was completed in Charles Sturt University Exercise Physiology Laboratory by the principal investigator who is an Exercise Sports Science Australia (ESSA) Accredited Exercise Scientist (AES) and was a PhD student at the time. They also have their Certificate in Pathology for venous blood collection.

Each session was 1 on 1 between the participants and principal investigator. Direct supervision was provided by the principal investigator and would monitor exercise adherence by recording HR and RPE every 5 minutes, and changing resistance when required throughout the HIIE.

This research was approved by the institutional ethic and biosafety committee.
Intervention code [1] 333552 0
Treatment: Other
Description of the comparator or control
The acute exercise intervention was compared to a healthy control group. Both the gastrointestinal group and healthy control group participated in the exercise interventions, MICE and HIIE. Each participant was randomised into a group, either MICE or HIIE, before crossing over to complete the other intervention.

Each session was face to face and individual (e.g., one participant and the principal investigator).

The two acute sessions were spaced 7-days apart and delivered at Charles Sturt University's Exercise Physiology Laboratory.

Every participant received a reminder the day before their session to ensure they remembered to fast.

Throughout the protocol, HR was monitored every 5 minutes by the principal investigator who was a PhD student in Human Movement at the time.
Control group
Active

Outcomes
Primary outcome [1] 344827 0
Inflammatory marker - Interleukin-1 receptor antagonist. A 22g catheter was inserted and secured into the medial antecubital vein for the collection of venous blood at pre, immediately post, and at 2h post-exercise. The 24h post-exercise blood sample was collected with a 21g winged butterfly needle. For each collection, approximately 25ml of blood were manually drawn by syringe, ejected, and aliquoted into ethylenediaminetetraacetic acid (EDTA) tubes and a serum-separating tube (SST). EDTA tubes were centrifuged immediately at 3500 rpm for 15min at 4°C; SST were left to clot for approximately 30min then centrifuged at 3500 rpm for 15min. Supernatants were immediately stored at -80°C until analysis. Samples were analysed in duplicate with a sandwich enzyme immunoassay technique (Thermo Scientific Multiskan FC), according to manufacturer’s instructions and analytical techniques for IL-1ra (Human IL-1ra ELISA Kit, product number RAB0283, Missouri 63103, USA). Intra-assay and inter-assay coefficients of variations were <10% and <12% for IL-1ra.
Timepoint [1] 344827 0
The timepoints for each protocol, both MICE and HIIE, were pre-exercise, immediately-post exercise completion, 2hrs post exercise completion and 24hrs post exercise completion. There was a 7-day rest between protocols.
Primary outcome [2] 345182 0
Inflammatory marker - Monocyte chemoattractant protein-1 A 22g catheter was inserted and secured into the medial antecubital vein for the collection of venous blood at pre, immediately post, and at 2h post-exercise. The 24h post-exercise blood sample was collected with a 21g winged butterfly needle. For each collection, approximately 25ml of blood were manually drawn by syringe, ejected, and aliquoted into ethylenediaminetetraacetic acid (EDTA) tubes and a serum-separating tube (SST). EDTA tubes were centrifuged immediately at 3500 rpm for 15min at 4°C; SST were left to clot for approximately 30min then centrifuged at 3500 rpm for 15min. Supernatants were immediately stored at -80°C until analysis. Samples were analysed in duplicate with a sandwich enzyme immunoassay technique (Thermo Scientific Multiskan FC), according to manufacturer’s instructions and analytical techniques for MCP-1 (Human MCP-1/CCL2 ELISA Kit, product number RAB0054, Missouri 63103, USA). Intra-assay and inter-assay coefficients of variations were <10% and <12% for MCP-1.
Timepoint [2] 345182 0
The timepoints for each protocol, both MICE and HIIE, were pre-exercise, immediately-post exercise completion, 2hrs post exercise completion and 24hrs post exercise completion. There was a 7-day rest between protocols.
Primary outcome [3] 345183 0
Inflammatory marker - Interleukin-17 A 22g catheter was inserted and secured into the medial antecubital vein for the collection of venous blood at pre, immediately post, and at 2h post-exercise. The 24h post-exercise blood sample was collected with a 21g winged butterfly needle. For each collection, approximately 25ml of blood were manually drawn by syringe, ejected, and aliquoted into ethylenediaminetetraacetic acid (EDTA) tubes and a serum-separating tube (SST). EDTA tubes were centrifuged immediately at 3500 rpm for 15min at 4°C; SST were left to clot for approximately 30min then centrifuged at 3500 rpm for 15min. Supernatants were immediately stored at -80°C until analysis. Samples were analysed in duplicate with a sandwich enzyme immunoassay technique (Thermo Scientific Multiskan FC), according to manufacturer’s instructions and analytical techniques for IL-17 high sensitively (IL-17HS; Human IL-17 Immunoassay, catalogue number HS170; Biotechne R&D Systems, Minneapolis, USA). Intra-assay and inter-assay coefficients of variations were 3.5% and 6.9% for IL-17HS.
Timepoint [3] 345183 0
The timepoints for each protocol, both MICE and HIIE, were pre-exercise, immediately-post exercise completion, 2hrs post exercise completion and 24hrs post exercise completion. There was a 7-day rest between protocols.
Secondary outcome [1] 459436 0
The Harvey-Bradshaw Index was utilised to assess Crohn's disease gastrointestinal symptoms.
Timepoint [1] 459436 0
Pre-exercise and 24-hrs post exercise completion for each protocol.
Secondary outcome [2] 461767 0
The Simple Clinical Colitis Activity Index was used to assessment ulcerative colitis gastrointestinal symptoms.
Timepoint [2] 461767 0
Pre-exercise and 24-hrs post exercise completion for each protocol.
Secondary outcome [3] 461768 0
The IBS-Symptom Severity Scale was used to assess irritable bowel syndrome symptoms.
Timepoint [3] 461768 0
Pre-exercise and 24-hrs post exercise completion for each protocol.

Eligibility
Key inclusion criteria
Inflammatory Bowel Disease Group:
Diagnosis and clearance for inflammatory bowel disease was by a general practitioner (GP) or specialist before participation in the study.

Irritable Bowel Syndrome Group:
Irritable bowel syndrome participants were screened for eligibility according to the Rome IV criteria.

Healthy Control Group:
Healthy control participants were free from cardiovascular disease, Type 2 diabetes mellitus, any form of cancer, thyroid disease, stroke, head trauma, epilepsy, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, other neuromotor disorders, and any other diseases or conditions associated with systemic inflammatory responses.




Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
All participants were excluded if they were pregnant or breast-feeding.

Healthy controls were excluded if they have any of the following: cardiovascular disease, Type 2 diabetes mellitus, any form of cancer, thyroid disease, stroke, head trauma, epilepsy, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, other neuromotor disorders, and any other diseases or conditions associated with systemic inflammatory responses.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a computer-generated allocation method (spin-the-wheel randomiser).
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Descriptive, DASS-21, HR response, and RPE data are reported the mean ± standard deviation (SD). Independent samples t-test were applied to determine significant differences between baseline characteristics. The Shapiro-Wilk W test was used to assess the assumption of normality. To assess normally distributed data, a mixed between-within subjects’ analysis of variance (ANOVA; groups x time) was used. Levene’s Test of Equality of Error Variances and Box’s Test of Equality of Covariance Matrices were used to assess volitation of the assumption of homogeneity of variances and were reported. Wilks’ Lamba test determine the interaction and main effects. Mauchly’s Test of Sphericity was applied for within-subject effects, if not assumed Greenhouse-Geisser adjustment was applied. A Tukey post hoc was applied when a significant group interaction was observed to identify the source of significance. In data that violated normality assumptions, such as the inflammatory markers, non-parametric statistical test, Friedman Test, was utilised to assess group and time interactions with Bonferroni correction applied. Kruskal-Wallis Test was used to determine significance in median percentage of change. All statistical analyses were performed using Statistical Package for the Social Sciences (SPSS; IMB SPSS Statistics for Windows, Version 27.0. Armonk, NY) with significance set at p < 0.05. A priori power analysis was completed using G*Power (G*Power v3.1.9.6).

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment postcode(s) [1] 45610 0
2795 - Bathurst

Funding & Sponsors
Funding source category [1] 312627 0
Government body
Name [1] 312627 0
Australia Government Research Training Program
Country [1] 312627 0
Australia
Funding source category [2] 321768 0
University
Name [2] 321768 0
Charles Sturt University Staff Give Scholarship
Country [2] 321768 0
Australia
Primary sponsor type
University
Name
Charles Sturt University
Address
Country
Australia
Secondary sponsor category [1] 314239 0
None
Name [1] 314239 0
Address [1] 314239 0
Country [1] 314239 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 311945 0
Charles Sturt University Human Research Ethics Committee
Ethics committee address [1] 311945 0
Ethics committee country [1] 311945 0
Australia
Date submitted for ethics approval [1] 311945 0
09/12/2021
Approval date [1] 311945 0
22/03/2022
Ethics approval number [1] 311945 0
H22003

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 122930 0
Dr Kelly Baker
Address 122930 0
Charles Sturt University - Panorama Avenue, Bathurst NSW 2795
Country 122930 0
Australia
Phone 122930 0
+61 2 6338 6018
Fax 122930 0
Email 122930 0
Contact person for public queries
Name 122931 0
Kelly Baker
Address 122931 0
Charles Sturt University - Panorama Avenue, Bathurst NSW 2795
Country 122931 0
Australia
Phone 122931 0
+61 2 6338 6018
Fax 122931 0
Email 122931 0
Contact person for scientific queries
Name 122932 0
Kelly Baker
Address 122932 0
Charles Sturt University - Panorama Avenue, Bathurst NSW 2795
Country 122932 0
Australia
Phone 122932 0
+61 2 6338 6018
Fax 122932 0
Email 122932 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• No requirements
What individual participant data might be shared?
• All de-identified individual participant data
What types of analyses could be done with individual participant data?
• Any type of analysis (i.e. no restrictions on data re-use)
• Systematic reviews and meta-analyses
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
No end date
Where can requests to access individual participant data be made, or data be obtained directly?
• Journal publication or its supplementary materials: When the manuscript is accepted and published into a journal, information on how to access research data will be made available.
Prior to manuscript publication, any requests can be emailed to the principal investigator Dr Kelly Baker via [email protected].


Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.